FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

16 letters match. Newest first.

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Eurofins SF Analytical Laboratories, Inc.

    FDA warned Eurofins SF Analytical Laboratories, a contract drug-testing lab, that it kept incomplete microbial test records and skipped required investigations.

    High risk
  5. Silgan Dispensing Systems

    Silgan Unicep Packaging was cited for manufacturing quality failures and unapproved new drugs after invalidated microbial tests and a fungal recall.

    High risk
  6. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  7. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  8. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  9. Bausch & Lomb Inc.

    FDA warns Bausch & Lomb of persistent microbial contamination and poor aseptic controls at its Tampa sterile drug plant.

    High risk
  10. Reliance Life Sciences Private Limited

    FDA warned India's Reliance Life Sciences over falsified microbiology records and aseptic failures in sterile drug production, prompting a recall.

    High risk
  11. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk
  12. FairyGene, Inc.

    FDA cites FairyGene, a Bristol, PA contract manufacturer, for unsanitary facility and cleaning practices and for selling five unapproved drug balms.

    High risk
  13. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk
  14. Pharmathen International S.A.

    FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.

    High risk
  15. JW Nutritional LLC

    FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.

    High risk
  16. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk